NEW APPROVED MENOPAUSAL THERAPIES IN CANADA - Bijuva and Imvexxy

Knight Therapeutics Inc. announced the launch of Imvexxy® and Bijuva®. In Canada, Imvexxy is for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). It is the only product in its therapeutic class to offer a 4 mcg and 10 mcg dose. BIJUVA® is the first Health-Canada approved combination of 1 mg of estradiol and 100 mg of micronized progesterone in a single daily oral capsule. It is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women with an intact uterus.